Pathology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy.
Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Histopathology. 2018 Nov;73(5):801-808. doi: 10.1111/his.13694. Epub 2018 Aug 27.
The diagnosis of breast cancer (BC) is based on clinical examination in combination with imaging, and confirmed by pathological assessment of core needle biopsy or fine-needle aspiration biopsy (FNAB). The biological profile of the lesion is needed to define the prognosis and establish therapy. Given the importance of an early and minimally invasive diagnosis, we aimed to verify whether the biological features detected in FNAB-derived cytological material reflect the biological characteristics of surgical samples.
We used immunohistochemistry and fluorescence in-situ hybridisation to study a panel of conventional biomarkers [oestrogen receptor (ER), progesterone receptor (PgR), Ki67, and human epidermal growth factor receptor 2 (HER2)] in FNAB-derived cytological samples included in cell blocks of 93 BC patients, and compared the results with those obtained from histological evaluation of the same parameters in surgical samples. Median immunopositive values of ER, PgR and Ki67 were similar in cell blocks and surgical samples. The concordance rates of ER and PgR between FNAB-derived cell blocks and histological samples were 98% and 84%, respectively. The concordance rates of Ki67 and HER2 between the two sample types were 90% and 96%, respectively. Tumour subtype classification for triple-negative and HER2-positive BCs in FNAB-derived cell blocks was always concordant with the subtype determined in surgical material.
We demonstrated that biological marker determination in FNAB-derived cell blocks is feasible, and provides useful information and comparable results to those obtained with histological evaluation. Given the low cost of the procedure and its minimal impact on patients, we believe that cytological samples could be used as an alternative to tissue samples for early BC biomarker evaluation.
乳腺癌(BC)的诊断基于临床检查结合影像学,并通过对核心针活检或细针抽吸活检(FNAB)的病理评估来确认。需要了解病变的生物学特征,以确定预后并制定治疗方案。鉴于早期和微创诊断的重要性,我们旨在验证 FNAB 获得的细胞学材料中检测到的生物学特征是否反映手术样本的生物学特征。
我们使用免疫组织化学和荧光原位杂交技术,研究了 93 例 BC 患者 FNAB 衍生的细胞学样本中细胞块中的一组常规生物标志物[雌激素受体(ER)、孕激素受体(PgR)、Ki67 和人表皮生长因子受体 2(HER2)],并将结果与手术样本中相同参数的组织学评估结果进行比较。ER、PgR 和 Ki67 的免疫阳性中位值在细胞块和手术样本中相似。FNAB 衍生细胞块和组织学样本中 ER 和 PgR 的一致性率分别为 98%和 84%。Ki67 和 HER2 在两种样本类型之间的一致性率分别为 90%和 96%。FNAB 衍生细胞块中三阴性和 HER2 阳性 BC 的肿瘤亚型分类与手术标本中确定的亚型始终一致。
我们证明了 FNAB 衍生细胞块中生物标志物的测定是可行的,并提供了与组织学评估相当的有用信息和结果。鉴于该程序的低成本和对患者的最小影响,我们认为细胞学样本可以替代组织样本用于早期 BC 生物标志物评估。